Guidelines for the Intravenous Application of Recombinant Tissue-type Plasminogen Activator (Alteplase), the Second Edition, October 2012: A Guideline from the Japan Stroke Society

Journal of Stroke and Cerebrovascular Diseases

Volumn 22, Issue 5, 2013, Pages 571-600

  Minematsu, Kazuo ^a   Toyoda, Kazunori ^a   Hirano, Teruyuki ^b   Kimura, Kazumi ^c   Kondo, Rei ^d   Mori, Etsuro ^e   Nakagawara, Jyoji ^a   Sakai, Nobuyuki ^f   Shiokawa, Yoshiaki ^g   Tanahashi, Norio ^h   Yasaka, Masahiro ⁱ   Katayama, Yasuo ^j   Miyamoto, Susumu ^k   Ogawa, Akira ^l   Sasaki, Makoto ^l   Suga, Sadao ^m   Yamaguchi, Takenori ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OITA UNIVERSITY   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d Yamagata City Hospital Saiseikan   (Japan)

^e TOHOKU UNIVERSITY   (Japan)

^f KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^g KYORIN UNIVERSITY   (Japan)

^h SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^j NIPPON MEDICAL SCHOOL   (Japan)

^k KYOTO UNIVERSITY   (Japan)

^l IWATE MEDICAL UNIVERSITY   (Japan)

^m TOKYO DENTAL COLLEGE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; DUTEPLASE;

AGE; ANTICOAGULANT THERAPY; AORTA DISSECTION; AORTA VALVE REGURGITATION; ARTICLE; BLEEDING TENDENCY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; ECHO PLANAR IMAGING; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPAN; MEDICAL EXAMINATION; MEDICAL HISTORY; META ANALYSIS (TOPIC); NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; INFORMED CONSENT; JAPAN; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; STROKE; THROMBOLYTIC THERAPY; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84879736237     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2013.04.001     Document Type: Article

References (171)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
2. T. Yamaguchi, E. Mori, and K. Minematsu Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial Stroke 37 2006 1810 1815
3. Guideline Committee of the Japan Stroke Society for IV rt-PA (alteplase) in acute ischemic stroke Guidelines for IV application of rt-PA (alteplase), October 2005 [in Japanese] Jpn J Stroke 27 2005 327 354
4. Y. Shinohara, T. Yanagihara, and K. Abe I. Stroke in general (Guidelines for the Management of Stroke 2009) J Stroke Cerebrovasc Dis 20 4 Suppl 2011 S7 S30
5. W. Hacke, M. Kaste, and C. Fieschi Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA 274 1995 1017 1025
6. W. Hacke, M. Kaste, and C. Fieschi Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II) Lancet 352 1998 1245 1251
7. W.M. Clark, S. Wissman, and G.W. Albers Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke JAMA 282 1999 2019 2026
8. G.W. Albers, V.N. Thijs, and L. Wechsler Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study Ann Neurol 60 2006 508 517
9. W. Hacke, M. Kaste, and E. Bluhmki Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
10. S.M. Davis, G.A. Donnan, and M.W. Parsons Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial Lancet Neurol 7 2008 299 309
11. The IST-3 Collaborative Group The benefits and harms of IV thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial Lancet 379 2012 2352 2363
12. H.P. Adams Jr., G. del Zoppo, and M.J. Alberts Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke 38 2007 1655 1711
13. European Stroke Organization (ESO) Executive Committee; ESO Writing Committee Guideline for management of ischaemic stroke and transient ischemic attack 2008 Cerebrovasc Dis 25 2008 457 507
14. Best Practices and Standards web site. Canadian best practice recommendations for stroke care. Available from http://www.strokebestpractices. ca/index.php/hyperacute-stroke-management/acute-thrombolytic-therapy/. Accessed April 23, 2013.
15. Stroke Foundation web site. Clinical guidelines for stroke management 2010. Available from http://www.strokefoundation.com.au/clinical-guidelines/. Accessed April 23, 2013.
16. G.W. Albers, V.E. Bates, and W.M. Clark IV tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study JAMA 283 2000 1145 1150
17. M.D. Hill, A.M. Buchan Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators Thrombolysis for acute ischemic stroke: Results of the Canadian Alteplase for Stroke Effectiveness Study CMAJ 172 2005 1307 1312
18. N. Wahlgren, N. Ahmed, and A. Dávalos Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study Lancet 369 2007 275 282
19. E. Mori, K. Minematsu, and J. Nakagawara Effects of 0.6 mg/kg IV alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II) Stroke 41 2010 461 465
20. J. Nakagawara, K. Minematsu, and Y. Okada Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-Marketing Alteplase Registration Study (J-MARS) Stroke 41 2010 1984 1989
21. K. Toyoda, M. Koga, and M. Naganuma Routine use of IV low-dose rt-PA in Japanese patients: General outcomes and prognostic factors from the SAMURAI register Stroke 40 2009 3591 3595
22. The Multicenter Acute Stroke Trial-Europe Study Group Thrombolytic therapy with streptokinase in acute ischemic stroke N Engl J Med 335 1996 145 150
23. E. Mori, Y. Yoneda, and M. Tabuchi Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke Neurology 42 1992 976 982
24. T. Yamaguchi, T. Hayakawa, and H. Kikuchi Intravenous tissue plasminogen activator ameliorates the outcome of hyperacute embolic stroke Cerebrovasc Dis 3 1993 269 272
25. T. Yamaguchi, H. Kikuchi, and T. Hayakawa Clinical efficacy and safety of IV tissue plasminogen activator in acute embolic stroke: A randomized, double-blind, dose-comparison study of duteplase T. Yamaguchi, E. Mori, K. Minematsu, Thrombolytic Therapy in Acute Ischemic Stroke III 1995 Springer-Verlag Tokyo, Japan 223 229
26. W. Hacke, A.J. Furlan, and Y. Al-Rawi Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study Lancet Neurol 8 2009 141 150
27. M. Parsons, N. Spratt, and A. Bivard A randomized trial of tenecteplase versus alteplase for acute ischemic stroke N Engl J Med 366 2012 1099 1107
28. W. Hacke, G. Donnan, and C. Fieschi Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials Lancet 363 2004 768 774
29. J.M. Wardlaw, G. del Zoppo, and T. Yamaguchi Thrombolysis for acute ischaemic stroke Cochrane Database Syst Rev 3 2003 CD000213
30. N. Wahlgren, N. Ahmed, and A. Davalos Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): An observational study Lancet 372 2008 1303 1309
31. K.R. Lees, E. Bluhmki, and R. von Kummer Time to treatment with IV alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials Lancet 375 2010 1695 1703
32. J.M. Wardlaw, V. Murray, and E. Berge Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-analysis Lancet 379 2012 2364 2372
33. European Stroke Organization (ESO) Executive Committee; ESO Writing Committee. Guideline for management of ischaemic stroke and transient ischemic attack 2008. Available from http://www.eso-stroke.org/pdf/ESO-Guideline-Update- Jan-2009.pdf. Accessed April 23, 2013.
34. G.J. del Zoppo, J.L. Saver, and E.C. Jauch Expansion of the time window for treatment of acute ischemic stroke with IV tissue plasminogen activator. A Science Advisory from the American Heart Association/American Stroke Association Stroke 40 2009 2945 2948
35. Guideline Committee of the Japan Stroke Society for IV rt-PA (alteplase) in acute ischemic stroke. Emergent statement on proper use of IV rt-PA (alteplase) in patients with ischemic stroke within 3 to 4.5 hours of symptom onset [in Japanese]. Available from http://www.jsts.gr.jp/img/info02.pdf. Accessed April 23, 2013.
36. E.C. Jauch, B. Cucchiara, and O. Adeoye Part 11: Adult stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Circulation 122 Suppl 3 2010 S818 S828
37. A. Meretoja, D. Strbian, and S. Mustanoja Reducing in-hospital delay to 20 minutes in stroke thrombolysis Neurology 79 2012 306 313
38. I.L. Katzan, A.J. Furlan, and L.E. Lloyd Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience JAMA 283 2000 1151 1158
39. G.D. Graham Tissue plasminogen activator for acute ischemic stroke in clinical practice: A meta-analysis of safety data Stroke 34 2003 2847 2850
40. M. Selim, J.N. Fink, and S. Kumar Predictors of hemorrhagic transformation after IV recombinant tissue plasminogen activator: Prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume Stroke 33 2002 2047 2052
41. D. Tanne, S.E. Kasner, and A.M. Demchuk Markers of increased risk of intracerebral hemorrhage after IV recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey Circulation 105 2002 1679 1685
42. N. Wahlgren, N. Ahmed, and N. Eriksson Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring Study (SITS-MOST) Stroke 39 2008 3316 3322
43. Y. Okada, T. Yamaguchi, and K. Minematsu Hemorrhagic transformation in cerebral embolism Stroke 20 1989 598 603
44. M. Tisserand, L. Le Guennec, and E. Touzé Prevalence of MRI-defined recent silent ischemia and associated bleeding risk with thrombolysis Neurology 76 2011 1288 1295
45. Y. Shinohara, and K. Minematsu A caution for appropriate i.v. application of alteplase for acute ischemic stroke: dissection of the thoracic aorta [in Japanese] Jpn J Stroke 30 2008 443 444
46. E. Mori, K. Minematsu, and J. Nakagawara Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: Evidence from the Japan Alteplase Clinical Trial (J-ACT) J Stroke Cerebrovasc Dis 20 2011 517 522
47. The NINDS t-PA Stroke Study Group Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial Stroke 28 1997 2119 2125
48. N.K. Mishra, N. Ahmed, and G. Andersen Thrombolysis in very elderly people: Controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive BMJ 341 2010 c6046
49. Karolinska Stroke Update web site. Consensus Statements 2010. Reperfusion therapy - Intravenous thrombolysis. Available from http://www.strokeupdate.org/ Cons-Reperf-IVT-2010.aspx. Accessed April 23, 2013.
50. P. Bhatnagar, D. Sinha, and R.A. Parker IV thrombolysis in acute ischaemic stroke: A systematic review and meta-analysis to aid decision making in patients over 80 years of age J Neurol Neurosurg Psychiatry 82 2011 712 717
51. M. Koga, Y. Shiokawa, and J. Nakagawara Low-dose IV recombinant tissue-type plasminogen activator therapy for patients with stroke outside European indications: Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rtPA Registry Stroke 43 2012 253 255
52. D.A. De Silva, J.J.F. Manzano, and H.M. Chang Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis Neurology 76 2011 1838 1840
53. N. Tsugita, S. Nagara, and K. Okamoto An autopsy case of cardiac rupture after IV rt-PA administration for acute ischemic stroke [in Japanese] Jpn J Stroke 33 2011 241 245
54. N.K. Mishra, P. Lyden, and J.C. Grotta Thrombolysis is associated with consistent functional improvement across baseline stroke severity: A comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA) Stroke 41 2010 2612 2617
55. K. Hashi How to think about revision of the package insert accompanying alteplase? [in Japanese] Jpn J Stroke 30 2008 786 788
56. P. Khatri, D.O. Kleindorfer, and S.D. Yeatts Strokes with minor symptoms: An exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials Stroke 41 2010 2581 2586
57. P.A. Barber, J. Zhang, and A.M. Demchuk Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility Neurology 56 2001 1015 1020
58. E.E. Smith, A.R. Abdullah, and I. Petkovska Poor outcomes in patients who do not receive IV tissue plasminogen activator because of mild or improving ischemic stroke Stroke 36 2005 2497 2499
59. V. Rajajee, C. Kidwell, and S. Starkman Early MRI and outcomes of untreated patients with mild or improving ischemic stroke Neurology 67 2006 980 984
60. J.Z. Willey, J. Stillman, and J.A. Rivolta Too good to treat? Outcomes in patients not receiving thrombolysis due to mild deficits or rapidly improving symptoms Int J Stroke 7 2012 202 206
61. G. Tsivgoulis, A.V. Alexandrov, and J. Chang Safety and outcomes of IV thrombolysis in stroke mimics: A 6-year, single-care center study and a pooled analysis of reported series Stroke 42 2011 1771 1774
62. K. Hashi Is it appropriate to exclude patients with unruptured intracranial aneurysms from the indication for IV thrombolysis with rt-PA for acute cerebral infarction? [in Japanese] Jpn J Stroke 30 2008 72 76
63. N.J. Edwards, H. Kamel, and A. Josephson The safety of IV thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: A case series and review of the literature Stroke 43 2012 412 416
64. The UCAS Japan Investigators The natural course of unruptured cerebral aneurysms in a Japanese cohort N Engl J Med 366 2012 2474 2482
65. A.M. Garcia, J.A. Egido, and M.E. Garcia Thrombolysis for ischaemic stroke and glioblastoma multiforme: a case report BMJ Case Rep 2009 2009 10.1136/bcr.06.2008.0268 [Epub 2009 Feb 23]
66. W. Neil, and B. Ovbiagele IV thrombolysis in ischemic stroke patients with intracranial neoplasms: Two cases and a literature review Case Report Med 2011 2011 503758
67. S. Uchiyama, S. Ibayashi, and M. Matsumoto Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation J Stroke Cerebrovasc Dis 21 2012 165 173
68. S. Sato, T. Uehara, and K. Toyoda Impact of the approval of IV recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: The Stroke Unit Multicenter Observational (SUMO) study Stroke 40 2009 30 34
69. Y. Iguchi, K. Kimura, and K. Shibazaki Increasing number of stroke specialists should contribute to utilization of IV rt-PA: Results of questionnaires from 1466 hospitals in Japan J Neurol Sci 279 2009 66 69
70. Y. Iguchi, K. Kimura, and K. Shibazaki The number of stroke physicians is the key to preparing IV rt-PA Cerebrovasc Dis 28 2009 460 467
71. Y. Okada, K. Minematsu, and A. Ogawa Nation-wide survey of use of IV rt-PA (alteplase) therapy during the first four years after approval: For overcoming regional gaps Jpn J Stroke 32 2010 365 372 [in Japanese]
72. M.J. Alberts, G. Hademenos, and R.E. Latchaw Recommendations for the establishment of primary stroke centers. Brain Attack Coalition JAMA 283 2000 3102 3109
73. H.J. Audebert, C. Kukla, and B. Vatankhah Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: The Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany Stroke 37 2006 1822 1827
74. H. Takao, Y. Murayama, and T. Ishibashi A new support system using a mobile device (smartphone) for diagnostic image display and treatment of stroke Stroke 43 2012 236 239
75. N. Miyamatsu, K. Kimura, and T. Okamura Effects of public education by television on knowledge of early stroke symptoms among a Japanese population aged 40 to 74 years: A controlled study Stroke 43 2012 545 549
76. H.K. Wall, B.M. Beagan, and J. O'Neill Addressing stroke signs and symptoms through public education: The Stroke Heroes Act FAST campaign Prev Chronic Dis 5 2008 A49
77. R.U. Kothari, A. Pancioli, and T. Liu Cincinnati prehospital stroke scale: Reproducibility and validity Ann Emerg Med 33 1999 373 378
78. K. Kimura, T. Inoue, and Y. Iguchi Kurashiki prehospital stroke scale Cerebrovasc Dis 25 2008 189 191
79. Y. Chen, V. Bogosavljevic, and D. Leys IV thrombolytic therapy in patients with stroke mimics: Baseline characteristics and safety profile Eur J Neurol 18 2011 1246 1250
80. T. Brott, H.P. Adams Jr., and C.P. Olinger Measurements of acute cerebral infarction: A clinical examination scale Stroke 20 1989 864 870
81. The NINDS t-PA Stroke Study Group Intracerebral hemorrhage after IV t-PA therapy for ischemic stroke Stroke 28 1997 2109 2118
82. T.G. Kwiatkowski, R.B. Libman, and M. Frankel Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group N Engl J Med 340 1999 1781 1787
83. K.D. Flemming, and R.D. Brown Jr. Acute cerebral infarction caused by aortic dissection: Caution in the thrombolytic era Stroke 30 1999 477 478
84. Y. Iguchi, K. Kimura, and K. Sakai Hyper-acute stroke patients associated with aortic dissection Intern Med 49 2010 543 547
85. N. Tomura, K. Uemura, and A. Inugami Early CT finding in cerebral infarction: Obscuration of the lentiform nucleus Radiology 168 1988 463 467
86. C.L. Truwit, A.J. Barkovich, and A. Gean-Marton Loss of the insular ribbon: Another early CT sign of acute middle cerebral artery infarction Radiology 176 1990 801 806
87. T. Moulin, F. Cattin, and T. Crepin-Leblond Early CT signs in acute middle cerebral artery infarction: Predictive value for subsequent infarct locations and outcome Neurology 47 1996 366 375
88. G. Gacs, A.J. Fox, and H.J. Barnett CT visualization of intracranial arterial thromboembolism Stroke 14 1983 756 762
89. B.D. Pressman, E.J. Tourje, and J.R. Thompson An early CT sign of ischemic infarction: Increased density in a cerebral artery AJR Am J Roentgenol 149 1987 583 586
90. G. Schuierer, and W. Huk The unilateral hyperdense middle cerebral artery: An early CT-sign of embolism or thrombosis Neuroradiology 30 1988 120 122
91. D. Leys, J.P. Pruvo, and O. Godefroy Prevalence and significance of hyperdense middle cerebral artery in acute stroke Stroke 23 1992 317 324
92. P.A. Barber, A.M. Demchuk, and M.E. Hudon Hyperdense sylvian fissure MCA "dot" sign: A CT marker of acute ischemia Stroke 32 2001 84 88
93. M.C. Leary, C.S. Kidwell, and J.P. Villablanca Validation of computed tomographic middle cerebral artery "dot" sign: An angiographic correlation study Stroke 34 2003 2636 2640
94. M. Koga, Y. Saku, and K. Toyoda Reappraisal of early CT signs to predict the arterial occlusion site in acute embolic stroke J Neurol Neurosurg Psychiatry 74 2003 649 653
95. J.M. Wardlaw, and O. Mielke Early signs of brain infarction at CT: Observer reliability and outcome after thrombolytic treatment-systematic review Radiology 235 2005 444 453
96. A. Ogawa, E. Mori, and K. Minematsu Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The middle cerebral artery embolisim local fibrinolytic intervention trial (MELT) Japan Stroke 38 2007 2633 2639
97. [in Japanese] A. Ogawa Standardization of stroke imaging and judgment for the MELT Japan. A report of the research project granted by the Ministry of Health, Labour and Welfare, Japan (2002) 2002 Iwate Medical University Morioka, Japan 41 44
98. R. von Kummer Effect of training in reading CT scans on patient selection for ECASS II Neurology 51 3 Suppl 3 1998 S50 S52
99. Acute Stroke Imaging Standardization Group-Japan [in Japanese] Practical guidelines for acute stroke imaging 2007 2007 Nanko-do Tokyo
100. P.A. Barber, A.M. Demchuk, and J. Zhang Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score Lancet 355 2000 1670 1674
101. J.H. Pexman, P.A. Barber, and M.D. Hill Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke AJNR Am J Neuroradiol 22 2001 1534 1542
102. M.D. Hill, P.A. Barber, and A.M. Demchuk Acute IV-intra-arterial revascularization therapy for severe ischemic stroke Stroke 33 2002 279 282
103. T. Hirano, T. Yonehara, and Y. Inatomi Presence of early ischemic changes on computed tomography depends on severity and the duration of hypoperfusion: A single photon emission-computed tomographic study Stroke 36 2005 2601 2608
104. M.A. Ezzeddine, M.H. Lev, and C.T. McDonald Extent of early ischemic changes on computed tomography (CT) before thrombolysis: Prognostic value of the Alberta Stroke Program Early CT Score in ECASS II Stroke 33 2002 959 966
105. P. Schramm, P.D. Schellinger, and E. Klotz Comparison of perfusion computed tomography and computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke of less than 6 hours' duration Stroke 35 2004 1652 1658
106. V. Larrue, R. von Kummer, and G. Del Zoppo Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study Stroke 28 1997 957 960
107. S.C. Patel, S.R. Levine, and B.C. Tilley Lack of clinical significance of early ischemic changes on computed tomography in acute stroke JAMA 286 2001 2830 2838
108. A.M. Demchuk, M.D. Hill, and P.A. Barber Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study Stroke 36 2005 2110 2115
109. I. Dzialowski, M.D. Hill, and S.B. Coutts Extent of early ischemic changes on computed tomography (CT) before thrombolysis: Prognostic value of the Alberta Stroke Program Early CT Score in ECASS II Stroke 37 2006 973 978
110. T. Hirano, M. Sasaki, and N. Tomura Low Alberta Stroke Program Early Computed Tomography Score within 3 hours of onset predicts subsequent sICH in patients treated with 0.6 mg/kg alteplase J Stroke Cerebrovasc Dis 21 2011 898 902
111. S. Warach, D. Chien, and W. Li Fast magnetic resonance diffusion-weighted imaging of acute human stroke Neurology 42 1992 1717 1723
112. S. Warach, J. Gaa, and B. Siewert Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging Ann Neurol 37 1995 231 241
113. H.L. Lutsep, G.W. Albers, and A. DeCrespigny Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke Ann Neurol 41 1997 574 580
114. P.A. Barber, D.G. Darby, and P.M. Desmond Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI Neurology 51 1998 418 426
115. G. Thomalla, P. Rossbach, and M. Rosenkranz Negative fluid-attenuated inversion recovery imaging identifies acute ischemic stroke at 3 hours or less Ann Neurol 65 2009 724 732
116. J. Aoki, K. Kimura, and Y. Iguchi IV thrombolysis based on diffusion-weighted imaging and fluid-attenuated inversion recovery mismatch in acute stroke patients with unknown onset time Cerebrovasc Dis 31 2011 435 441
117. C.S. Kidwell, J.A. Chalela, and J.L. Saver Comparison of MRI and CT for detection of acute intracerebral hemorrhage JAMA 292 2004 1823 1830
118. M.C. Arnould, C.B. Grandin, and A. Peeters Comparison of CT and three MR sequences for detecting and categorizing early (48 hours) hemorrhagic transformation in hyperacute ischemic stroke AJNR Am J Neuroradiol 25 2004 939 944
119. J.B. Fiebach, P.D. Schellinger, and A. Gass Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: A multicenter study on the validity of stroke imaging Stroke 35 2004 502 506
120. K.H. Cho, J.S. Kim, and S.U. Kwon Significance of susceptibility vessel sign on T2*-weighted gradient echo imaging for identification of stroke subtypes Stroke 36 2005 2379 2383
121. M. Sasaki, M. Ida, and K. Yamada Standardizing display conditions of diffusion-weighted images using concurrent b0 images: A multi-vendor multi-institutional study Magn Reson Med Sci 6 2007 133 137
122. P.A. Barber, M.D. Hill, and M. Eliasziw Imaging of the brain in acute ischaemic stroke: Comparison of computed tomography and magnetic resonance diffusion-weighted imaging J Neurol Neurosurg Psychiatry 76 2005 1528 1533
123. T. Nezu, M. Koga, and J. Nakagawara Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving IV recombinant tissue-type plasminogen activator therapy: Stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry Stroke 42 2011 2196 2200
124. M.P. Marks, D.C. Tong, and C. Beaulieu Evaluation of early reperfusion and i.v. tPA therapy using diffusion- and perfusion-weighted MRI Neurology 52 1999 1792 1798
125. C.S. Kidwell, J.L. Saver, and J. Mattiello Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging Ann Neurol 47 2000 462 469
126. H. Ma, M.W. Parsons, and S. Christensen A multicentre, randomized, double-blinded, placebo-controlled phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) Int J Stroke 7 2012 74 80
127. R.E. Latchaw, M.J. Alberts, and M.H. Lev Recommendations for imaging of acute ischemic stroke: A scientific statement from the American Heart Association Stroke 40 2009 3646 3678
128. P.D. Schellinger, G. Thomalla, and J. Fiehler MRI-based and CT-based thrombolytic therapy in acute stroke within and beyond established time windows: An analysis of 1210 patients Stroke 38 2007 2640 2645
129. T. Nezu, M. Koga, and K. Kimura Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry Neurology 75 2010 555 561
130. K. Kimura, Y. Iguchi, and K. Shibazaki Large ischemic lesions on diffusion-weighted imaging done before IV tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke Stroke 39 2008 2388 2391
131. J. Fiehler, G.W. Albers, and J.M. Boulanger Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): Pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients Stroke 38 2007 2738 2744
132. K. Kimura, Y. Iguchi, and K. Shibazaki M1 susceptibility vessel sign on T2* as a strong predictor for no early recanalization after IV-t-PA in acute ischemic stroke Stroke 40 2009 3130 3132
133. K. Kimura, Y. Sakamoto, and J. Aoki Clinical and MRI predictors of no early recanalization within 1 hour after tissue-type plasminogen activator administration Stroke 42 2011 3150 3155
134. T. Ueda, T. Hatakeyama, and Y. Kumon Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by initial SPECT Stroke 25 1994 298 303
135. A.V. Alexandrov, C.A. Molina, and J.C. Grotta Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke N Engl J Med 351 2004 2170 2178
136. J. Eggers, I.R. Konig, and B. Koch Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plasminogen activator in acute middle cerebral artery main stem occlusion: Results from a randomized study Stroke 39 2008 1470 1475
137. G.J. del Zoppo, K. Poeck, and M.S. Pessin Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke Ann Neurol 32 1992 78 86
138. I. Linfante, R.H. Llinas, and M. Selim Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after IV tissue plasminogen activator Stroke 33 2002 2066 2071
139. M. Saqqur, K. Uchino, and A.M. Demchuk Site of arterial occlusion identified by transcranial Doppler predicts the response to IV thrombolysis for stroke Stroke 38 2007 948 954
140. M. Rubiera, M. Ribo, and R. Delgado-Mederos Tandem internal carotid artery/middle cerebral artery occlusion: An independent predictor of poor outcome after systemic thrombolysis Stroke 37 2006 2301 2305
141. T. Nakashima, K. Toyoda, and M. Koga Arterial occlusion sites on magnetic resonance angiography influence the efficacy of IV low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke Int J Stroke 4 2009 425 431
142. K. Kimura, Y. Iguchi, and K. Shibazaki Early recanalization rate of major occluded brain arteries after IV tissue plasminogen activator therapy using serial magnetic resonance angiography studies Eur Neurol 62 2009 287 292
143. M. Koga, K. Toyoda, and T. Nakashima Carotid duplex ultrasonography can predict outcome ofIV alteplase therapy for hyperacute stroke J Stroke Cerebrovasc Dis 20 2011 24 29
144. T. Hirano, M. Sasaki, and E. Mori Residual vessel length on magnetic resonance angiography identifies poor responders to alteplase in acute middle cerebral artery occlusion patients: Exploratory analysis of the Japan Alteplase Clinical Trial II Stroke 41 2010 2828 2833
145. Miyamoto S. A report from the Research on Bioethics in Severe Stroke research group. 2012.
146. M. Yong, and M. Kaste Association of characteristics of blood pressure profiles and stroke outcomes in the ECASS-II trial Stroke 39 2008 366 372
147. N. Ahmed, N. Wahlgren, and M. Brainin Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with IV thrombolysis: Retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR) Stroke 40 2009 2442 2449
148. Y. Tomii, K. Toyoda, and T. Nakashima Effects of hyperacute blood pressure and heart rate on stroke outcomes after IV tissue plasminogen activator J Hypertens 29 2011 1980 1987
149. T. Ogihara, K. Kikuchi, and H. Matsuoka The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) Hypertens Res 32 2009 3 107
150. S.M. Zinkstok, Y.B. Roos on behalf of the ARTIS investigators Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: A randomized controlled trial Lancet 380 2012 731 737
151. A.D. Barreto, A.V. Alexandrov, and P. Lyden The argatroban and tissue-type plasminogen activator stroke study: Final results of a pilot safety study Stroke 43 2012 770 775
152. A.M. Lopez-Yunez, A. Bruno, and L.S. Williams Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage Stroke 32 2001 12 16
153. L.B. Morgenstern, J.C. Hemphill 3rd, and C. Anderson Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 41 2010 2108 2129
154. A. Furlan, R. Higashida, and L. Wechsler Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism JAMA 282 1999 2003 2011
155. R.C. Lisboa, B.D. Jovanovic, and M.J. Alberts Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke Stroke 33 2002 2866 2871
156. M.G. Lansberg, M.J. O'Donnell, and P. Khatri Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e601S e636S
157. C.A. Lewandowski, M. Frankel, and T.A. Tomsick Combined IV and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial Stroke 30 1999 2598 2605
158. IMS Study Investigators Combined IV and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study Stroke 35 2004 904 911
159. The IMS II Trial Investigators The Interventional Management of Stroke (IMS) II study Stroke 38 2007 2127 2135
160. R.T. Higashida, A.J. Furlan, and H. Roberts Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke Stroke 34 2003 e109 e137
161. Japan Stroke Society website. Guidelines for MERCI Retriever. Available from http://www.jsts.gr.jp/img/meric.pdf [in Japanese]. Accessed April 23, 2013.
162. Japan Stroke Society website. Guidelines for Penumbra System. Available from http://www.jsts.gr.jp/img/penumbra.pdf [in Japanese]. Accessed April 23, 2013.
163. W.S. Smith, G. Sung, and S. Starkman Safety and efficacy of mechanical embolectomy in acute ischemic stroke result of the MERCI Trial Stroke 36 2005 1432 1440
164. W.S. Smith, G. Sung, and J. Saver Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI Trial Stroke 39 2008 1205 1212
165. Z.S. Shi, Y. Loh, and G. Walker Endovascular thrombectomy for acute ischemic stroke in failed IV tissue plasminogen activator versus non-IV tissue plasminogen activator patients: Revascularization and outcomes stratified by the site of arterial occlusions Stroke 41 2010 1185 1192
166. Penumbra Pivotal Stroke Trial Investigators The penumbra pivotal stroke trial: Safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease Stroke 40 2009 2761 2768
167. M. Goyal, B.K. Menon, and S.B. Coults Effect of baseline CT scan appearance and time to recanalization on clinical outcomes in endovascular thrombectomy of acute ischemic strokes Stroke 42 2011 93 97
168. R. Tarr, D. Hsu, and Z. Kulcsar The POST trial: Initial post-market experience of the Penumbra system: Revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe J Neurointerv Surg 2 2010 341 344
169. J.L. Saver, R. Jahan, and E.I. Levy Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial Lancet 380 2012 1241 1249
170. R.G. Nogueira, H.L. Lutsep, and R. Gupta Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): A randomised trial Lancet 380 2012 1231 1240
171. F. Nahab, G.A. Walker, and J.E. Dion Safety of periprocedural heparin in acute ischemic stroke endovascular therapy: The Multi MERCI Trial J Stroke Cerebrovasc Dis 21 2012 790 793